Class I histone deacetylases (HDACs-1-3) play an important role in steroid hormone–dependent gene expression and in modulating cell survival and proliferation. We analyzed their expression in a tissue microarray including 74 endometriosis samples and 30 normal endometrium controls. The mean HDAC-1 immunoreactivity score (IRS ± standard deviation) was 7.6 ± 2.5 in endometriosis and 5.3 ± 2.3 in normal endometrium (P < .001). In contrast, the IRSs of HDAC-2 and -3 were 11.7 ± 0.7 and 11.8 ± 1.1 in endometriosis and 11.6 ± 1.0 and 11.9 ± 0.4 in normal endometrium (P = .7 and P = .2), respectively. Significant correlations were found between HDAC-1 and estrogen (-alpha/-beta) and progesterone receptor expression. In conclusion, HDAC-1, but not HDAC-2/-3, was significantly increased in endometriosis and associated with steroid hormone receptor expression that may reflect interdependence. In context with the literature, specific inhibitors of HDAC-1 may have inhibitory activities similar to those of broad-spectrum HDAC inhibitors and may be clinically tolerated, which would increase their chance as an option in the treatment of endometriosis.
BulunSE. Endometriosis. N Engl J Med. 2009;360(3):268–279.
3.
EskenaziBWarnerML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am. 1997;24(2):235–258.
4.
GiudiceLC.Clinical practice. Endometriosis. N Engl J Med. 2010;362(25):2389–2398.
5.
GuoSW. Epigenetics of endometriosis. Mol Hum Reprod. 2009;15(10):587–607.
6.
de RuijterAJvan GennipAHCaronHNKempSvan KuilenburgAB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370(pt 3):737–749.
7.
LiuXFBagchiMK. Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem. 2004;279(15):15050–15058.
8.
SulimanBAXuDWilliamsBR. HDACi: molecular mechanisms and therapeutic implications in the innate immune system. Immunol Cell Biol. 2012;90(1):23–32.
9.
ArrowsmithCHBountraCFishPVLeeKSchapiraM. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11(5):384–400.
10.
KawanoYNasuKLiHApplication of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target. Hum Reprod. 2011;26(9):2486–2498.
11.
ImeschPFinkDFedierA. Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertil Steril. 2010;94(7):2838–2842.
12.
ImeschPSamartzisEPSchneiderMFinkDFedierA. Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin. Fertil Steril. 2011;95(5):1579–1583.
13.
SoaresSRMartínez-VareaAHidalgo-MoraJJPellicerA. Pharmacologic therapies in endometriosis: a systematic review. Fertil Steril. 2012;98(3):529–555.
14.
KhanNJeffersMKumarSDetermination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008;409(2):581–589.
15.
WittaSEJotteRMKonduriKRandomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012;30(18):2248–2255.
16.
SamartzisNSamartzisEPNoskeAExpression of the G protein-coupled estrogen receptor (GPER) in endometriosis: a tissue microarray study. Reprod Biol Endocrinol. 2012;10:30.
17.
SamartzisEPSamartzisNNoskeALoss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?Mod Pathol. 2012;25(6):885–892.
18.
SamartzisNImeschPDedesKJExpression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study. BMC Cancer. 2011;11:463.
19.
LiuXGuoSW. A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril. 2008;89(1):246–250.
20.
LiuXNieJGuoSW. Elevated immunoreactivity against class I histone deacetylases in adenomyosis. Gynecol Obstet Invest. 2012;74(1):50–55.
21.
de LevalLWaltregnyDBoniverJYoungRHCastronovoVOlivaE.Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus. Am J Surg Pathol. 2006;30(3):319–327.
22.
WaltregnyDDe LevalLGlénissonWExpression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol. 2004;165(2):553–564.
23.
Colón-DíazMBáez-VegaPGarcíaMHDAC1 and HDAC2 are differentially expressed in endometriosis. Reprod Sci. 2012;19(5):483–492.
24.
NisolleMDonnezJ. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril. 1997;68(4):585–596.
25.
BradnerJEWestNGrachanMLChemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6(3):238–243.
26.
HubbertCGuardiolaAShaoRHDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455–458.
27.
KovacsJJMurphyPJGaillardSHDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18(5):601–607.
28.
LiuMLiuXZhangYGuoSW. Valproic acid and progestin inhibit lesion growth and reduce hyperalgesia in experimentally induced endometriosis in rats. Reprod Sci. 2012;19(4):360–373.
29.
WuYGuoSW. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol. 2008;137(2):198–203.
